Human LRRK2 cDNA

Studies have shown that mutations in the LRRK2 gene are the most common determinants of late-onset Parkinsons disease (PD) susceptibility. These cDNA vectors comprise wild type LRRK2 cDNA or mutated LRRK2 cDNA that can be expressed in cells to decipher the biochemical pathways and pathology of PD. Other advantages include:

• Produced from human source material and cloned into a mammalian expression vector
• Mutated LRRK2 cDNA contains R1441C mutation localized in the GTPase domain and the G2019S mutations located in the mixed-lineage kinase MLK- like domain
• Contains a Myc-tag gene for convenient detection of expressed myc-tagged LRRK2 polypeptides in assays
• Useful as research tools to better understand neurodegenerative mechanisms relevant to PD
• Could potentially be used to produce recombinant LRRK2 proteins useful to produce and test specific antibodies

 

Category(s):